Literature DB >> 16520854

Antihypertensive medications and blood sugar: theories and implications.

David F Blackburn1, Thomas W Wilson.   

Abstract

Increased rates of diabetes have been reported with thiazide diuretics and beta-blockers, but not with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or calcium channel blockers. These observations are important because significant glycemic effects of drugs may be a source of accelerated cardiovascular risk that is not detectable during restricted clinical trial follow-up periods. The extent to which diabetes is affected by these medications remains unclear, as is the precise mechanism by which diabetes is promoted. However, several plausible theories are presented herein. Although drug-induced diabetes has been a concern for several years, not enough information is available to influence prescribing for the majority of patients. The number one priority should be controlling blood pressure in a timely manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520854      PMCID: PMC2528930          DOI: 10.1016/s0828-282x(06)70902-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  51 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

3.  Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group.

Authors:  P J Savage; S L Pressel; J D Curb; E B Schron; W B Applegate; H R Black; J Cohen; B R Davis; P Frost; W Smith; N Gonzalez; G P Guthrie; A Oberman; G Rutan; J L Probstfield; J Stamler
Journal:  Arch Intern Med       Date:  1998-04-13

Review 4.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

5.  Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension.

Authors:  L J Dominguez; M Barbagallo; S J Jacober; D B Jacobs; J R Sowers
Journal:  Am J Hypertens       Date:  1997-12       Impact factor: 2.689

6.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Authors:  George L Bakris; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Jackson T Wright; Rosemary Oakes; Mary Ann Lukas; Karen M Anderson; David S H Bell
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

7.  Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension.

Authors:  S J Hunter; R Harper; C N Ennis; E Crothers; B Sheridan; G D Johnston; A B Atkinson; P M Bell
Journal:  J Hypertens       Date:  1998-01       Impact factor: 4.844

8.  Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients.

Authors:  Y Miyazaki; H Murakami; A Hirata; M Fukuoka; A Masuda; N Ura; K Shimamoto
Journal:  Am J Hypertens       Date:  1998-08       Impact factor: 2.689

9.  Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.

Authors:  R Fogari; A Zoppi; L Corradi; P Lazzari; A Mugellini; P Lusardi
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

10.  ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.

Authors:  R Fogari; A Zoppi; P Lazzari; P Preti; A Mugellini; L Corradi; P Lusardi
Journal:  J Cardiovasc Pharmacol       Date:  1998-10       Impact factor: 3.105

View more
  17 in total

1.  Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study.

Authors:  Jie V Zhao; Fangchao Liu; C Mary Schooling; Jianxin Li; Dongfeng Gu; Xiangfeng Lu
Journal:  Diabetologia       Date:  2022-01-26       Impact factor: 10.122

2.  Hypertension, but not body mass index, is predictive of increased pancreatic lipid content and islet dysfunction.

Authors:  Daniel M Tremmel; Austin K Feeney; Samantha A Mitchell; Peter J Chlebeck; Sierra A Raglin; Luis A Fernandez; Jon S Odorico; Sara D Sackett
Journal:  Am J Transplant       Date:  2019-12-16       Impact factor: 8.086

Review 3.  Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers.

Authors:  Philippe E R Lheureux; Soheil Zahir; Mireille Gris; Anne-Sophie Derrey; Andrea Penaloza
Journal:  Crit Care       Date:  2006-05-22       Impact factor: 9.097

4.  Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications.

Authors:  Hasniza Zaman Huri; Doris Yew Hui Ling; Wan Azman Wan Ahmad
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

5.  Systolic Blood Pressure and Risk of Type 2 Diabetes: A Mendelian Randomization Study.

Authors:  Rachael C Aikens; Wei Zhao; Danish Saleheen; Muredach P Reilly; Stephen E Epstein; Emmi Tikkanen; Veikko Salomaa; Benjamin F Voight
Journal:  Diabetes       Date:  2016-10-04       Impact factor: 9.461

Review 6.  Metabolic syndrome and its associated factors in Ethiopia: A systematic review and meta-analysis.

Authors:  Tadeg Jemere; Belayneh Kefale
Journal:  J Diabetes Metab Disord       Date:  2021-05-09

7.  Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study.

Authors:  Soulmaz Fazeli Farsani; Patrick C Souverein; Marja M J van der Vorst; Aukje K Mantel-Teeuwisse; Catherijne A J Knibbe; Anthonius de Boer
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

8.  Severe diltiazem poisoning treated with hyperinsulinaemia-euglycaemia and lipid emulsion.

Authors:  Nadine Monteiro; Joana Silvestre; João Gonçalves-Pereira; Camila Tapadinhas; Vitor Mendes; Pedro Póvoa
Journal:  Case Rep Crit Care       Date:  2013-05-20

9.  Antihypertensive Drug Use and New-Onset Diabetes in Female Patients with Coronary Artery Disease: A Population-based Longitudinal Cohort Study.

Authors:  Yi-Sheng Liou; Hung-Yi Chen; Lyun Tien; Yi-Sian Gu; Gwo-Ping Jong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

10.  Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients.

Authors:  Sandesh Madhukar Bharati; Nishith Singh
Journal:  J Pharmacol Pharmacother       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.